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nine patients participated in the study, of which 49 (28 with gastric ulcer and 21 with duodenal ulcer) received eradication therapy and 50 (27 with gastric ulcer and 23 with duodenal ulcer) received maintenance therapy. In the eradication therapy group, the male-to-female ratio was 48/1 and the age was 45.9 years (range: 19 -61). In the maintenance therapy group, the male-to-female ratio was 50/0 and the age was 45.0 years (range: 20 -62).
Study design
This was a prospective observational study. The patients effectively chose their preferred treatment. Patients who agreed and positively hoped for eradication therapy received this, while those that hesitated received maintenance therapy. The study was set in a single centre, the on-site occupational health clinic. Follow-up continued for 12 months. The author did not report any loss to follow-up.
Analysis of effectiveness
The basis of the analysis was the actual treatment received. The primary outcomes were the number of patients successfully eradicated, the number of patients remaining symptom free at the end of the 1-year observation period, and the lifetime probability of ulcer recurrence. The author reported that the two groups of patients had similar demographic and clinical characteristics.
Effectiveness results
For the H. pylori group, eradication was successful in 42 (86%) patients and remained successful after 1 year in 41 (84%) patients.
For the RAN therapy group, symptomatic ulcer recurrence occurred during continuous therapy for 12 months in 12 (24%) patients.
The lifetime probability of ulcer recurrence was 6.1% with H. pylori eradication and 24.0% with RAN alone.
Clinical conclusions
The author concluded that H. pylori was successfully eradicated in 86% of patients, and 98% of these patients remained symptom free for the 1-year study period. In addition, the lifetime probability of ulcer recurrence was significantly reduced with eradication therapy.
Modelling A decision analytic model was constructed in Excel 5.0 to estimate the financial and clinical outcomes for 1 year after each initial management strategy, H. pylori eradication or RAN.
Measure of benefits used in the economic analysis
The author did not estimate a summary measure of benefit. In effect, a cost-consequences analysis conducted.
Direct costs
A perspective for the costing was not reported. The author did not state whether discounting was carried out, although discounting was not necessary since the time horizon was one year. The author estimated the cost of treating patients with H. pylori eradication and RAN maintenance therapy. Then identified likely patient pathways that included followup treatments and estimated the cost of H. pylori and RAN treatment strategies. The cost estimates were derived from direct payments identified by medical receipts for services received, and were therefore based on actual data. The direct medical costs included all medical tests and drugs. The unit costs were reported separately and the quantities were determined in the decision analytic model. A price year was not reported.
